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95, 62, 55 days respectively. Most of the application represented new generic drugs 
(252, 213, 264, 225 pieces). Between 2005–2008 the average delay for new generic 
drugs was 75, 64, 58, 56 days. CONCLUSIONS: The introduction of EU transparency 
directive provided a strong regulatory framework for decision-making process on drug 
reimbursement. In the simpliﬁed procedure we did not found signiﬁcant differences 
in time delay of decision according to submission categories. However, in 2007 the 
average delay signiﬁcantly decreased compared to previous years.
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OBJECTIVES: This study aims to conduct a descriptive analysis of the policy environ-
ment surrounding the generic medicines retail market in Portugal. The policy analysis 
focuses on supply-side measures (i.e. market access, pricing, reference-pricing and 
reimbursement of generic medicines) and demand-side measures (i.e. incentives for 
physicians to prescribe, for pharmacists to dispense and for patients to use generic 
medicines). METHODS: The policy analysis was based on an international literature 
review. Also, a simulation exercise was carried out to compute potential savings from 
substituting generic for originator medicines in Portugal using IMS Health data. 
RESULTS: Portugal has developed a successful generic medicines market by increasing 
reimbursement of generic medicines (until October 2005), by introducing a reference-
pricing system, by encouraging physicians to prescribe by international non- 
proprietary name (INN), and by allowing generic substitution by pharmacists. 
However, the development of the generic medicines market has been hindered by the 
existence of copies, pricing regulation, certain features of the reference-pricing system, 
weak incentives for physicians to prescribe generic medicines and a ﬁnancial disincen-
tive for pharmacists to dispense generic medicines. Increased generic substitution 
would be expected to reduce public expenditure on originator medicines by 45%. 
CONCLUSIONS: The development of the Portuguese generic medicines market has 
mainly been fuelled by supply-side measures. To support the further expansion of the 
market, policy makers need to strengthen demand-side measures inciting physicians 
to prescribe, pharmacists to dispense and patients to use generic medicines.
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OBJECTIVES: Biologic agents have helped revolutionize the treatment of a number 
of chronic and acute diseases. These highly valued products have also placed a signiﬁ-
cant cost burden on health care systems. For example, the average annual price of 
TNFs in the EU5 is a12,400 per patient (MSP). Payers, understandably, are eagerly 
awaiting the arrival of biosimilars. However, because of their biologic nature, biosimi-
lars are not exact copies of the drugs they seek to emulate. This important difference 
between biosimilars and traditional generics has resulted in greater requirements for 
regulatory approval and has led some markets to take positions on their (non) inter-
changeability. Given these dynamics, this research explores likely price discounts of 
anticipated biosimilars, provides an analysis of what lessons can be taken from tradi-
tional generics and forecasts how biosimilars might change the standard of care for 
their respective therapy areas. METHODS: Review the EMEA data requirements and 
current prices of biosimilars on the European market. Review current biosimilar 
environment, including a review of current biosimilar pricing and uptake. Limited 
primary research. RESULTS: The most commonly anticipated price discount of 
biosimilars is 20–30% to the parent drug. This expectation is largely driven by past 
experience with biosimilar human growth hormones, erythropoietins and G-CSFs. 
CONCLUSIONS: Biosimilars will introduce a new competitive dynamic to the bio-
logic market. However, because of the considerably higher cost of bringing biosimilars 
to market and the potential to differentiate biosimilars, the initial price discount of 
biosimilars will be more similar to a me-too like pricing strategy as opposed to what 
has been seen with competitive generic markets (e.g. ﬂuoxetine). Importantly, even at 
a 20–30% discount, there will be sufﬁcient cost-savings to encourage the use of 
biosimilars over their parent drug.
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OBJECTIVES: To prepare detailed analysis of parallel trade of pharmaceuticals in 
Poland and to build a model calculating direct and indirect savings resulting from this 
phenomenon. METHODS: Diligent analysis of parallel trade based on data provided 
by IMS Health and gathered from The Polish Ofﬁce for Registration of Medical 
Products, Medical Devices and Biocidal Products preceded by systematic literature 
review. RESULTS: Parallel import (PI) of pharmaceuticals in Poland has been possible 
since Poland became an EU member in May 2004. Since that date the PI licences have 
been granted for 352 medicines in Poland (73% prescription medicines, 20% OTC, 
5% hospital and 2% veterinary). Currently, there are 18 parallel traders operating on 
the Polish market although only 5 have a signiﬁcant share. Pharmaceuticals offered 
by parallel importers in Poland are exported mainly from Greece (33%), the Czech 
Republic (17%), France (12%), and the UK (12%). The share of parallel trade in total 
pharmaceutical market reached 0.5% in January 2009 compared to 0.3% in Decem-
ber 2007. The sales value from parallel import was PLN 82 million in 2008. Available 
analyses prove that medicines from parallel trade are cheaper than original products 
in Poland by about 20 to 60%. Up to now, there were no scientiﬁc studies of savings, 
resulting from parallel import in Poland. Detailed study on this topic is planned in 
cooperation with recognized European experts on parallel trade—University of South-
ern Denmark researchers. CONCLUSIONS: Parallel import is expected to grow in 
the next few years in Poland. Therefore, it is necessary to implement a reliable model 
of support for parallel importers by means of appropriate directives introduced by the 
Polish Government. In order to convince decision-makers that parallel import could 
be a source of substantial savings a detailed study is going to be conducted according 
to methodology mentioned above.
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OBJECTIVES: Diffusion of electronic patient record (EPR) systems is almost universal 
in ambulatory medical services in Israel. The drug prescription module of the most 
widely-used EPR system has an intervention capacity of electronically notifying physi-
cians about generic or therapeutic drug substitutions. This notiﬁcation is triggered 
when the physician’s ﬁrst choice of a prescribed drug does not meet preferences of the 
health maintenance organization (HMO). The objective of this paper was to study 
whether and how such an intervention can inﬂuence physicians’ drug prescription 
habits and help contain costs. METHODS: We monitored system use for 40 consecu-
tive weeks in the second largest HMO in Israel, covering more than 1.2 million pre-
scriptions, and recorded physicians’ willingness to comply and prescribe a substitute 
drug in response to the system’s notiﬁcation. RESULTS: Findings show that electronic 
notiﬁcations about substitutes can change physicians’ drug prescription habits toward 
compliance with HMO preferences. Higher physician compliance was found for 
generic substitutes than for therapeutic substitutes. Moreover, compliance was based 
on a cognitive decision process triggered upon notiﬁcation. Examining the notiﬁcation 
and deciding whether to comply or not lasted 2 to 5 seconds, hence not time consum-
ing. An increase in compliance over time, until stabilization, was also observed. The 
direct ﬁnancial savings on drug expenditures were estimated at 4.7%, mostly for 
chronic drugs, implying long-term saving. CONCLUSIONS: The results show that 
embedding notiﬁcations about substitute drugs in an EPR’s drug prescription module 
can be effective and impact drug prescription behavior toward compliance, yet this 
compliance is context-dependent rather than automatic. In addition, long-term cost 
containment can be achieved without decreasing the quality of care.
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OBJECTIVES: In Korea, Positive List System(PLS) was introduced as a drug listing 
system in Jan 2007. This study aimed to comparatively analyze the impact of the PLS 
introduction on the listing of incrementally modiﬁed drugs(IMD) and new drugs(ND). 
METHODS: Database for new drug coverage assessment was established based on 
selective drug listing assessment data from HIRA website and MOHW reference 
publications. They analyzed the two-year drug listing data submitted to the Drug 
Review and Evaluation Committee (2007.1.2008.12) since the introduction of PLS. 
SAS version 9.1 was used for descriptive analysis and logistic regression in statistical 
analysis. RESULTS: After the introduction of PLS, success rate of coverage decision 
was 74.6% and 50.6% for IMD and ND, respectively; for drug price agreement rate, 
73.6% and 85.0%; for ﬁnal drug listing rate, 54.9% and 43.0%, placing IMD higher 
than ND. Time to coverage decision for IMD and ND was 109.0days and 155.7days, 
respectively; time to drug listing was 192.9days and 260.0days, respectively, indicating 
much shorter time to decision and listing for IMD than general ND. The ﬁnal listing 
rate was 52.1% for multinational pharmaceutical companies while being 48.6% for 
domestic drug makers. The factors having the largest inﬂuence on insurance listing 
were cost-effectiveness for IMD and ﬁnancial impact for ND. CONCLUSIONS: The 
introduction of PLS resulted in higher coverage rate and shorter time to ﬁnal listing 
for IMD compared to ND. The factors affecting the insurance listing differed between 
IMD and MD, with cost-effectiveness being the major factor for IMD.
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OBJECTIVES: Recent advances in embryonic stem cell based therapies are moving 
regenerative medicine based products into clinical trials and closer to entering the 
pharmaceutical arena. As these therapies edge closer to entering the market, it is 
important that appropriate health technology assessments are in place to deal with 
these new market entrants. Both autologous and allogenic products are under develop-
ment, however, this analysis will focus on allogenic products and the challenges they 
will face. Allogenic products are derived from cells or tissues and likely to be marketed 
“off the shelf,” similar to conventional biopharmaceutical products. While regulatory 
